PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
302.55%
Net income growth above 1.5x CRK's 163.70%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
191.13%
D&A growth well above CRK's 2.90%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.94%
Both reduce yoy usage, with CRK at -94.71%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.94%
Negative yoy usage while CRK is 0.00%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-410.39%
Both negative yoy, with CRK at -72.70%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
314.66%
Operating cash flow growth above 1.5x CRK's 84.51%. David Dodd would confirm superior cost control or stronger revenue-to-cash conversion.
-219.89%
Both yoy lines negative, with CRK at -38.97%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
-4400.93%
Negative yoy acquisition while CRK stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
129.98%
Growth of 129.98% while CRK is zero at 0.00%. Bruce Berkowitz sees a moderate difference requiring justification by ROI in these smaller invests.
-216.10%
Both yoy lines negative, with CRK at -37.06%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
218.27%
Lower share issuance yoy vs. CRK's 725.47%, implying less dilution. David Dodd would confirm the firm still has enough capital for expansions.
No Data
No Data available this quarter, please select a different quarter.